In this state, priming with the HDAC inhibitor vorinostat is no longer able to restore JNK signaling, suggesting that an alternative approach will likely be needed to sensitize relapsed neuroblastomas to standard-of-care chemotherapies. This evidence concerns the gene HDAC9 and neuroblastoma.